NCT06569524 Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 120 participants in total. It began in 2023-09-14 with a primary completion date of 2026-12.

Brief Summary

A randomized, double-blind, placebo-controlled Phase II study，to evaluate the efficacy and safety of TQA2225/AP025 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Eligibility Criteria

Inclusion Criteria: * Must be willing to participate in the study and provide written informed consent. * Male or female aged 18 ≤ age \< 75 at the time of signing the informed consent. * Must have had prior liver biopsy within 180 days of randomization with fibrosis stage 1 to 3 and a NAS of ≥4 with at least a score of 1 in each of the lobular inflammation and ballooning degeneration. * Confirmation of ≥10% liver fat content on Magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF). * Weight changes≤5% in the 6 weeks prior to randomization. * No qualitative change in dose for the drugs listed below: 1. Antidiabetic treatment if glucagon-like peptide-1 receptor agonists (GLP1 receptor agonists) or sodium-glucose co-transporter-2 inhibitors (SGLT2 inhibitors): for at least 3 months 2. Vitamin E (if at a dose ≥400 IU/day): for at least 6 months 3. Statins: for at least 3 months * Females of childbearing potential must practice a consistent and proper use of highly effective method of contraception throughout the study and for 6 month after treatment discontinuation. Exclusion Criteria: * Documented causes of chronic liver disease other than NASH * Type 1 diabetes or uncontrolled Type 2 diabetes defined as:Hemoglobin A1c ≥9% at screening，Fasting blood glucose≥13.9mmol/l * Uncontrolled hypertension at Screening (values ≥160/100 mm Hg) * History or presence of cirrhosis * Subjects with any type of active malignancy or a history of malignancy (except cervical cancer or non-metastatic cutaneous squamous cell carcinoma, basal cell carcinoma and papillary thyroid carcinoma) that has been cured for more than 5 years prior to the screening period; * Unable or unwilling to undergo liver biopsy according to research requirements. * History of weight loss surgery within 5 years (inclusive) prior to screening * A major surgery was performed 3 months prior to signing the Informed Consent Form (ICF), or planned during the study period. * Have experienced any bone trauma, fracture, or bone surgery within ≤ 2 months prior to screening. * When screening, according to the results of dual energy X-ray absorptiometry (DXA) examination, it meets the criteria for osteoporosis: T≤ -2.5 * Recent history of drug abuse (defined as ≤ 2 years). * Patient participating in other clinical trials of drugs or medical devices within 3 months prior to screening. * Abnormal laboratory test values：ALT or AST \>5 × ULN；Serum ALP≥2× ULN；eGFR\<60mL/min；INR\>1.3× ULN；platelets \< LLN. * Pregnant or breastfeeding women. * Liver transplantation history or planned liver transplantation * Contraindications for MRI examination * Any other condition which, in the opinion of the Investigator, would impede compliance, hinder completion of the study, compromise the well-being of the patient, or interfere with the study outcomes.

Contact & Investigator

Frequently Asked Questions

Related Trials